BIOHARVEST SCIENCES INC.
BHSTNasdaq
$2.70
↓ -4.6%Jul 17 close · end-of-day
Price
1Y↓ -61.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$34.5M
Net Income (TTM)
-$11.1M
Free Cash Flow (TTM)
-$9.6M
Gross Margin
—
Operating Margin
-16.2%
Net Margin
-32.3%
ROE
-43.8%
ROIC
-171.2%
Debt / Equity
0.0
Net Cash
$22.9M
Return 1Y
-60.9%
Company profile
BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada.
- CEO
- Ilan Sobel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- British Columbia
- Website
- bioharvest.com
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $12.7M | $25.2M | $34.5M |
| Gross profit | — | — | — |
| Operating income | -$10.0M | -$7.0M | -$5.6M |
| Net income | -$12.6M | -$12.9M | -$11.1M |
| Diluted EPS | — | — | — |
| Operating cash flow | -$8.5M | -$6.7M | -$7.2M |
| Free cash flow | -$10.0M | -$9.5M | -$9.6M |
| Gross margin | — | — | — |
| Operating margin | -78.6% | -27.7% | -16.2% |
| Net margin | -99.1% | -51.3% | -32.3% |
No quarterly data.
Company news
Jul 15, 2026
Jun 18, 2026
May 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.